Abstract
In Europe more than 3 million individuals develop a malignancy annually. Despite recent progress in screening, diagnosis and therapy of most cancers, prognosis remains poor and only a minority of patients are cured. This owes to the fact that most cancers are diagnosed in advanced stages and due to the fact that treatment options for most cancers are limited. While there has been a substantial improvement in systemic therapy for many cancers it remains difficult to assess the potential responsiveness of the cancers towards these newly developed drugs, which include small molecules and monoclonal antibodies. Therefore various strategies have been developed in order to assess the prognosis and predict the expected tumor response in order to individualize the treatment, thereby offering the patient a tailored therapy which accounts for the tumor- and patient-specific morphological and molecular characteristics of the disease. This review summarizes recent efforts, challenges and limitations of proteome analysis in the assessment of prognosis and response-prediction in human cancers.
Keywords: Proteomics, translational oncology, prediction, prognosis, biomarker
Current Cancer Drug Targets
Title: Application of Proteome Analysis to the Assessment of Prognosis and Response Prediction in Clinical Oncology
Volume: 8 Issue: 2
Author(s): Christoph Rocken, Ralf Ketterlinus and Matthias P.A. Ebert
Affiliation:
Keywords: Proteomics, translational oncology, prediction, prognosis, biomarker
Abstract: In Europe more than 3 million individuals develop a malignancy annually. Despite recent progress in screening, diagnosis and therapy of most cancers, prognosis remains poor and only a minority of patients are cured. This owes to the fact that most cancers are diagnosed in advanced stages and due to the fact that treatment options for most cancers are limited. While there has been a substantial improvement in systemic therapy for many cancers it remains difficult to assess the potential responsiveness of the cancers towards these newly developed drugs, which include small molecules and monoclonal antibodies. Therefore various strategies have been developed in order to assess the prognosis and predict the expected tumor response in order to individualize the treatment, thereby offering the patient a tailored therapy which accounts for the tumor- and patient-specific morphological and molecular characteristics of the disease. This review summarizes recent efforts, challenges and limitations of proteome analysis in the assessment of prognosis and response-prediction in human cancers.
Export Options
About this article
Cite this article as:
Rocken Christoph, Ketterlinus Ralf and Ebert P.A. Matthias, Application of Proteome Analysis to the Assessment of Prognosis and Response Prediction in Clinical Oncology, Current Cancer Drug Targets 2008; 8 (2) . https://dx.doi.org/10.2174/156800908783769328
DOI https://dx.doi.org/10.2174/156800908783769328 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Related Books
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Using Small Molecule GSK3β Inhibitors to Treat Inflammation
Current Medicinal Chemistry Advances in Vaccine Adjuvants For Infectious Diseases
Current HIV Research Why Some Messages Speak Better: Child Immunization in the News and on the Internet
Current Drug Safety Thioredoxin and Thioredoxin Reductase As Redox-Sensitive Molecular Targets for Cancer Therapy
Current Pharmaceutical Design Mechanisms Used by Human Papillomaviruses to Escape the Host Immune Response
Current Cancer Drug Targets Therapeutic Application of Intrabodies Against Age-Related Neurodegenerative Disorders
Current Pharmaceutical Design Nifedipine Blocks Ondansetron Electrophysiological Effects in Rabbit Purkinje Fibers and Decreases Early Afterdepolarization Incidence
Current Clinical Pharmacology Vasculogenic and Angiogenic Pathways in Moyamoya Disease
Current Medicinal Chemistry Epothilones: From Discovery to Clinical Trials
Current Topics in Medicinal Chemistry Multifuntional Nanoparticles: Preparation and Applications in Biomedicine and in Non-Invasive Bioimaging
Recent Patents on Nanotechnology Schiff Bases and their Metal Complexes as Potential Anticancer Candidates: A Review of Recent Works
Anti-Cancer Agents in Medicinal Chemistry Reposition of the Fungicide Ciclopirox for Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Non-coding RNAs in Exosomes: New Players in Cancer Biology
Current Genomics Malignancy Risk in Systemic Lupus: Recent Research and Ongoing Challenges
Current Rheumatology Reviews Carcinoma of the Lower Uterine Segment (LUS): Clinicopathological Characteristics and Association with Lynch Syndrome
Current Genomics The Quest for Surrogate Markers of Angiogenesis: A Paradigm for Translational Research in Tumor Angiogenesis and Anti- Angiogenesis Trials
Current Molecular Medicine White Poplar (Populus alba L.) Suspension Cultures as a Model System to Study Apoptosis Induced by Alfalfa Saponins
Anti-Cancer Agents in Medicinal Chemistry Motor Unit and Neuromuscular Junction Remodeling with Aging
Current Aging Science Cancer Stem Cells: The Emerging Challenge of Drug Targeting
Current Medicinal Chemistry Base Excision Repair: Contribution to Tumorigenesis and Target in Anticancer Treatment Paradigms
Current Medicinal Chemistry